Relmada Therapeutics, Inc.

Relmada Therapeutics, Inc.

We are a late-stage biotech company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). Our experienced and dedicated team is committed to making a difference in the lives of patients and their families. Our most advanced program is REL-1017, a novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels associated with major depressive disorder (MDD), while maintaining physiological glutamatergic neurotransmission. We believe that REL-1017 has the potential to transform the current neuropharmacological approach to MDD, and we are rapidly advancing toward investigating REL-1017 for potential indications as adjunctive and monotherapy.

Company details

2222 Ponce de Leon Blvd.,Coral Gables,33134

Find locations servedoffice locations

Business Type:
Technology
Industry Type:
Clinical Services
Market Focus:
Globally (various continents)

Contact supplier

Drop file here or browse